Epstein-Barr virus-specific T cells for the management of Epstein-Barr virus lymphomas

Current Opinion in Oncology

Volumn 13, Issue 5, 2001, Pages 349-353

  Finberg, Robert W ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN;

ANTIGEN EXPRESSION; B LYMPHOCYTE; CELL SURFACE; EPSTEIN BARR VIRUS; HODGKIN DISEASE; LATENT VIRUS INFECTION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT TRANSFORMATION; PHENOTYPE; PRIORITY JOURNAL; REED STERNBERG CELL; REVIEW; VIRUS INFECTION;

ANTIGENS, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, B-CELL; ORGAN TRANSPLANTATION; T-LYMPHOCYTES;

EID: 0034871648     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200109000-00006     Document Type: Review

References (40)

1. The Epstein-Barr virus and its association with human cancers
2. Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD)
3. Classification of the posttransplant lymphoproliferative disorders: From the past to the present
4. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: Analysis of the HLA class I processing pathway and the effects of interleukin-10 of Epstein-Barr virus-specific cytotoxic T-cell recognition
5. Detection of Epstein-Barr virus in Hodgkin Reed-Sternberg cells
6. Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation
7. The abnormal gene in X-linked lymphoproliferative syndrome
8. Primary immunodeficiency diseases and Epstein-Barr virus-induced lymphoproliferative disorders
9. Vaccine strategies against Epstein-Barr virus-associated diseases: Lessons from studies on cytotoxic T-cell-mediated immune regulation
10. Human CD4+ T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1
11. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
12. Developing immunotherapeutic strategies for the control of Epstein-Barr virus-associated malignancies
13. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts
14. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease
15. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease
16. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
17. Feasibility of cellular adoptive immunotherapy for Epstein-Barr virus-associated lymphomas using haploidentical donors
18. Adoptive immunotherapy for Epstein-Barr virus-related lymphoma
19. Adoptive immunotherapy following aliogeneic bone marrow transplantation
20. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response
21. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
22. Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant
23. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene, modified virus-specific T lymphocytes
24. Transplantation-related lymphoproliferative disorder: A model for human immunodeficiency virus-related lymphomas
25. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
26. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones
27. Deficient cellular immunity-finding and fixing the defects
28. Immunotherapy of human viral and malignant disease with genetically modified T-cell clones
29. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation
30. Donor T cells to treat EBV-associated lymphoma
31. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease
32. Immunotherapy for Epstein-Barr virus-associated cancers
33. Reconstitution of the cellular immune response after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin's lymphoma
34. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients
35. Effective treatment of high-grade lymphoproliferative disorder after renal transplantation using autologous lymphokine-activated killer cell therapy
36. Hodgkin's disease and peripheral T-cell lymphoma: Composite lymphoma with evidence of Epstein-Barr virus infection
37. Expression of Epstein-Barr virus (EBV) transcripts encoding homologues to important human proteins in diverse EBV associated diseases
38. Accessing Epstein-Barr virus-specific T cell memory with peptide-loaded dendritic cells
39. Fusions of human ovarian carcinoma cells with autologous or aliogeneic dendritic cells induce antitumor immunity
40. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes